摘要
2006-06-01,国家SFDA发布了停止鱼腥草注射液临床应用的公告,将组织对该类药品进行再评价。本文就鱼腥草注射液可能引起不良反应的几个方面进行机理探讨。
SFDA Noticed to stop using the Yuxingcao Injection in clinic, and orginazined to evalue the medicine in June 1, 2006. The mechanism of caused the ADR of the Yuxingcao Injection was studied in this paper.
出处
《中国药事》
CAS
2008年第5期435-436,共2页
Chinese Pharmaceutical Affairs